SIGA Technologies Logo
US8269171067
919473
SIGA

SIGA Technologies

Previsión

Comprar
  1
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • SIGA Technologies pays special dividend of $0.60 per share

    The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Más en de.investing.com


  • SIGA Technologies posts annual profit of $23 million despite quarterly loss

    SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Más en de.investing.com


  • SIGA Technologies reports strong 2025 results and remains debt-free

    SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Más en de.investing.com


  • SIGA Technologies: stock falls despite strong revenue growth in third quarter

    SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » Más en de.investing.com


  • SIGA Technologies reports stable quarterly results and remains financially solid

    SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » Más en de.investing.com

En 2026, SIGA Technologies ya ha pagado 0,51 € en dividendos. El último pago fue en abril.

Datos financieros

En el último trimestre, SIGA Technologies tuvo unos ingresos de 1,16 M € y un beneficio neto de -2,55 M €

(EUR) septiembre de 2026
YoY
Ingresos 1,16 M 47,92 %
Beneficio bruto 654,46 mil 52,53 %
Beneficio neto -2,55 M 52,91 %
EBITDA -4,84 M 30,85 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
156,84 M €
Número de acciones
71,86 M
Máximo/mínimo de 52 semanas
6,48 € - 2,16 €
Rentabilidad por dividendo
19,83 %
Dividendos TTM
0,51 €
Beta
1,02
Ratio P/E
374,22
Ratio PEG
-3,43
Ratio P/B
1,05
Ratio P/S
3,29

Perfil de la empresa

SIGA Technologies, Inc., una empresa farmacéutica en fase comercial, se centra en los mercados de seguridad sanitaria y enfermedades infecciosas en los Estados Unidos. Su producto principal es TPOXX, un antiviral de administración oral para el tratamiento de la viruela humana causada por el virus variola. SIGA Technologies, Inc. mantiene una alianza estratégica con Cipla Therapeutics para ofrecer innovación sostenida y acceso a fármacos antibacterianos, principalmente frente a amenazas biológicas. La empresa se fundó en 1995 y tiene su sede en Nueva York, Nueva York.

Nombre
SIGA Technologies
CEO
Diem Nguyen
Sede New York City, ny
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
10/09/1997
Empleados 49

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
SIGA
🍪

Parqet  usa cookies. Más información